Novagali Pharma Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
50
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$4.34M
- Investors
-
1
Novagali Pharma General Information
Description
Operator of a pharmaceutical company committed to developing and commercializing ophthalmic innovative products for all segments of the eye. The company specializes in the research, development, testing, production, and marketing of emulsion drugs that address the numerous needs of patients suffering from ocular conditions, thereby helping ophthalmologists to improve the lives of their patients.
Contact Information
Website
www.novagali.comCorporate Office
- 1 Rue Pierre Fontaine
- Genavenir IV, Evry Cedex
- 91058 Paris
- France
Corporate Office
- 1 Rue Pierre Fontaine
- Genavenir IV, Evry Cedex
- 91058 Paris
- France
Novagali Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 06-Jan-2012 | $4.34M | Completed | Generating Revenue | ||
| 7. Merger/Acquisition | 11-Oct-2011 | Completed | Generating Revenue | |||
| 6. IPO | 21-Jul-2010 | Completed | Generating Revenue | |||
| 5. Grant | 01-Apr-2010 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 26-Sep-2009 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 01-Apr-2006 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 20-Sep-2004 | $17.3M | $21.1M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Jan-2000 | $3.84M | $3.84M | Completed | Product Development |
Novagali Pharma Patents
Novagali Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20080107738-A1 | Cationic ophthalmic oil-in-water type emulsion; colloid particles, oily core surrounded by interfacial film; poloxamers, tyloxapol non ionic surfactant; prostaglandin is latanoprost, unoprostone isopropyl; chitosan, chlorhexidine, benzalkonium halide, vegetable oils; eye drops, ointment, ophthalmic gel | Active | 09-Nov-2004 |
Novagali Pharma Signals
Novagali Pharma Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 123 Investment Managers | Asset Manager | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| Auriga Partners (Paris) | Venture Capital | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| CDC Enterprises | PE/Buyout | Minority |
Novagali Pharma FAQs
-
When was Novagali Pharma founded?
Novagali Pharma was founded in 2000.
-
Where is Novagali Pharma headquartered?
Novagali Pharma is headquartered in Paris, France.
-
What is the size of Novagali Pharma?
Novagali Pharma has 50 total employees.
-
What industry is Novagali Pharma in?
Novagali Pharma’s primary industry is Drug Discovery.
-
Is Novagali Pharma a private or public company?
Novagali Pharma is a Private company.
-
What is the current valuation of Novagali Pharma?
The current valuation of Novagali Pharma is .
-
What is Novagali Pharma’s current revenue?
The current revenue for Novagali Pharma is .
-
How much funding has Novagali Pharma raised over time?
Novagali Pharma has raised $98.3M.
-
Who are Novagali Pharma’s investors?
123 Investment Managers, Andera Partners, Auriga Partners (Paris), Bpifrance, and CDC Enterprises are 5 of 14 investors who have invested in Novagali Pharma.
-
When was Novagali Pharma acquired?
Novagali Pharma was acquired on 06-Jan-2012.
-
Who acquired Novagali Pharma?
Novagali Pharma was acquired by Santen Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process